Silexion Therapeutics Corp (SLXN)

$0.84 -0.03 (-3.75%)
Market Cap 7.60M
Revenue (ttm) 0.00
Net Income (ttm) -16.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.15
Volume 101,200
Avg Vol 1,992,134
Day's Range N/A - N/A
Shares Out 8.69M
Stochastic %K 28%
Beta 0.12
Analysts Strong Sell
Price Target $5.00

Company Profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 674 3430
Fax: 972 2 643 0982
Address:
The Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Medical Center, Jerusalem, Israel
bwdrew
bwdrew Jun. 14 at 7:53 PM
$ALZN $HBIO $HCTI $SLXN $STRM
2 · Reply
Pig2market
Pig2market Jun. 12 at 10:27 PM
$SLXN garbage. I want my money back.
0 · Reply
SkyLonger
SkyLonger Jun. 11 at 2:57 PM
$SLXN tick tock ...🚀
0 · Reply
stupidusername
stupidusername Jun. 9 at 7:26 PM
$SLXN dead in here, so it’s going to explode. :)
0 · Reply
stocksense2
stocksense2 Jun. 6 at 8:19 PM
$SLXN Going under?
0 · Reply
max315
max315 Jun. 6 at 12:33 PM
$SLXN this thing still trading I see.
0 · Reply
IHSSMFs
IHSSMFs Jun. 3 at 11:29 PM
$SLXN Does anyone have a timeline re the next steps/dates for the clinical trials and testing that is being done in collaboration with the French company that SLXN is partnering with ?
0 · Reply
Pig2market
Pig2market Jun. 3 at 4:57 PM
$SLXN this pig just never holds any gains.
0 · Reply
Gated_Lambo
Gated_Lambo Jun. 3 at 4:24 PM
$SLXN
0 · Reply
max315
max315 Jun. 3 at 1:49 PM
$SLXN dead both ways until official ruling I suppose
0 · Reply
Latest News on SLXN
PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 22, 2025, 3:46 PM EDT - 25 days ago

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

May 21, 2025, 8:45 AM EDT - 26 days ago

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:45 PM EDT - 4 weeks ago

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Apr 23, 2025, 9:20 AM EDT - 7 weeks ago

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Mar 28, 2025, 8:30 AM EDT - 2 months ago

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Mar 21, 2025, 8:30 AM EDT - 3 months ago

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 18, 2025, 4:29 PM EDT - 3 months ago

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Mar 17, 2025, 8:15 AM EDT - 3 months ago

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Mar 5, 2025, 12:05 PM EST - 3 months ago

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Mar 5, 2025, 8:30 AM EST - 3 months ago

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Mar 3, 2025, 8:30 AM EST - 3 months ago

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Feb 25, 2025, 8:30 AM EST - 3 months ago

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Jan 29, 2025, 5:30 PM EST - 4 months ago

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Jan 29, 2025, 9:59 AM EST - 4 months ago

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Jan 28, 2025, 8:29 AM EST - 4 months ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

Jan 16, 2025, 12:08 PM EST - 5 months ago

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Jan 16, 2025, 11:04 AM EST - 5 months ago

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Jan 16, 2025, 8:51 AM EST - 5 months ago

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

LUV

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Jan 15, 2025, 8:00 PM EST - 5 months ago

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Jan 15, 2025, 4:01 PM EST - 5 months ago

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 13, 2025, 7:50 AM EST - 5 months ago

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Dec 17, 2024, 9:36 AM EST - 6 months ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

AMGN

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Nov 22, 2024, 4:30 PM EST - 7 months ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Nov 20, 2024, 8:30 AM EST - 7 months ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Oct 1, 2024, 6:45 AM EDT - 9 months ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Sep 24, 2024, 9:25 AM EDT - 9 months ago

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

Sep 24, 2024, 7:30 AM EDT - 9 months ago

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Sep 9, 2024, 7:32 AM EDT - 10 months ago

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Sep 3, 2024, 4:05 PM EDT - 10 months ago

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

Aug 15, 2024, 4:05 PM EDT - 10 months ago

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

bwdrew
bwdrew Jun. 14 at 7:53 PM
$ALZN $HBIO $HCTI $SLXN $STRM
2 · Reply
Pig2market
Pig2market Jun. 12 at 10:27 PM
$SLXN garbage. I want my money back.
0 · Reply
SkyLonger
SkyLonger Jun. 11 at 2:57 PM
$SLXN tick tock ...🚀
0 · Reply
stupidusername
stupidusername Jun. 9 at 7:26 PM
$SLXN dead in here, so it’s going to explode. :)
0 · Reply
stocksense2
stocksense2 Jun. 6 at 8:19 PM
$SLXN Going under?
0 · Reply
max315
max315 Jun. 6 at 12:33 PM
$SLXN this thing still trading I see.
0 · Reply
IHSSMFs
IHSSMFs Jun. 3 at 11:29 PM
$SLXN Does anyone have a timeline re the next steps/dates for the clinical trials and testing that is being done in collaboration with the French company that SLXN is partnering with ?
0 · Reply
Pig2market
Pig2market Jun. 3 at 4:57 PM
$SLXN this pig just never holds any gains.
0 · Reply
Gated_Lambo
Gated_Lambo Jun. 3 at 4:24 PM
$SLXN
0 · Reply
max315
max315 Jun. 3 at 1:49 PM
$SLXN dead both ways until official ruling I suppose
0 · Reply
Pig2market
Pig2market Jun. 3 at 1:34 PM
$SLXN what a dog. Sheesh. Another dead end stock. Get me out of this thing already.
0 · Reply
SkyLonger
SkyLonger Jun. 3 at 1:00 AM
$SLXN pure manipulation and fear....this will surprise 🤙
0 · Reply
IHSSMFs
IHSSMFs Jun. 2 at 8:38 PM
$SLXN We apparently have an extended “life” (___ days?). Let’s hope the SLXN leadership makes good use of it!!!
1 · Reply
stocksense2
stocksense2 Jun. 2 at 7:12 PM
$SLXN
0 · Reply
stocksense2
stocksense2 Jun. 2 at 6:42 PM
$SLXN Delisting coming?
2 · Reply
IHSSMFs
IHSSMFs Jun. 2 at 5:42 PM
$SLXN Output/findings of the French company/partner!!!
0 · Reply
stupidusername
stupidusername Jun. 2 at 5:38 PM
$SLXN what’s the next catalyst? Seems like the market ignored the preclinical
0 · Reply
IHSSMFs
IHSSMFs Jun. 2 at 3:40 PM
$SLXN Think how BIG this can/will be if/when the clinical trials are done and the results are verified 🤑🤑🤑! Patience!!!
0 · Reply
premarketmaker
premarketmaker Jun. 2 at 3:18 PM
$SLXN Shorts using fear to cover.
0 · Reply
Pig2market
Pig2market Jun. 2 at 2:52 PM
$SLXN news? What's happening? Let's go!
0 · Reply
IHSSMFs
IHSSMFs Jun. 2 at 2:39 PM
$SLXN Makes sense!!! Need a PR and a 180 day extension 🚀!!! Time is our “challenge” … not the product!!! Let’s go!!!
0 · Reply
PiXeLsalaT
PiXeLsalaT Jun. 2 at 1:51 PM
$SLXN I guess the appeal was successful, otherwise we would not be trading now. SEC: shares and warrants would be suspended AT THE OPENING of business on June 2, 2025.
0 · Reply